ArticleOncology letters2026
SOX2-positive upper tract urothelial carcinoma: Clinicopathological characteristics and therapeutic implications.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Upper tract urothelial carcinoma (UTUC) is a rare subtype of urothelial malignancy associated with poor prognosis, particularly in advanced stages. Sex determining region-Y-related high mobility group box 2 (SOX2), a key transcription factor involved in the maintenance of cellular stemness, has been identified as a potential biomarker in multiple cancer types; however, its prognostic significance in UTUC remains unclear. The present study aimed to investigate the expression pattern of SOX2 in UTUC and examine its association with clinicopathological characteristics. Moreover, the present study aimed to evaluate the association of SOX2 with programmed cell death ligand 1 (PD-L1) and antibody-drug conjugate (ADC) targets, including Nectin-4 and trophoblast cell surface antigen 2, to explore potential therapeutic implications. A total of 87 patients with UTUC who underwent radical nephroureterectomy were retrospectively analyzed. SOX2 expression was assessed using immunohistochemistry with a 10% cut-off value. Notably, SOX2 expression was detected in 24% (21/87) of cases. No significant associations were observed between SOX2 expression and clinicopathological parameters, molecular subtypes, or the expression of PD-L1 and ADC targets, except for hydronephrosis grade. Patients with SOX2-positive tumors exhibited significantly worse overall survival (OS), cancer-specific survival (CSS) and recurrence-free survival (RFS; P=0.004, P=0.005 and P=0.011, respectively) during a median follow-up period of 39.3 months. The 5-year CSS rates were 69% in the SOX2-negative group and 43% in the SOX2-positive group. Multivariate analysis identified SOX2 expression as an independent prognostic factor for CSS (P=0.001). Among patients who did not receive perioperative chemotherapy, those with SOX2-positive tumors demonstrated significantly poorer OS, CSS and RFS, compared with SOX2-negative patients. These findings indicated that SOX2 expression represents an independent and robust prognostic biomarker in UTUC, identifying a biologically distinct high-risk subgroup with unfavorable clinical outcomes. The preserved expression of PD-L1 and ADC targets in this subgroup may suggest potential responsiveness to immune checkpoint inhibitors and ADC-based therapies, supporting the consideration of intensified perioperative or systemic treatment strategies in SOX2-positive patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.